UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Vertebrate Ndc80 Complex Contains Spc24 and Spc25 Homologs, which Are Required to Establish and Maintain Kinetochore-Microtubule Attachment

Current biology, 2004-01, Vol.14 (2), p.131-137

2004

Volltextzugriff (PDF)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e007047

2023

Volltextzugriff (PDF)

Influence of cyclin type and dose on mitotic entry and progression in the early Drosophila embryo

The Journal of cell biology, 2009-03, Vol.184 (5), p.639-646

2009

Volltextzugriff (PDF)

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

Blood, 2002-04, Vol.99 (8), p.2670-2676

2002

Volltextzugriff (PDF)

Measuring the stoichiometry and physical interactions between components elucidates the architecture of the vertebrate kinetochore

Molecular biology of the cell, 2005-10, Vol.16 (10), p.4882-4892

2005

Volltextzugriff (PDF)

831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A870-A871

2021

Volltextzugriff (PDF)

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A30-A31

2021

Volltextzugriff (PDF)

28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A33-A33

2021

Volltextzugriff (PDF)

Microenvironmental regulation of tumour immunity and response to immunotherapy

The Journal of pathology, 2021-07, Vol.254 (4), p.374-383

2021

Volltextzugriff (PDF)

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

The Lancet (British edition), 2021-10, Vol.398 (10308), p.1344-1357

2021

Volltextzugriff (PDF)

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Journal of clinical oncology, 2021-02, Vol.39 (6), p.619-630

2021

Volltextzugriff (PDF)

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Journal of thoracic oncology, 2020-08, Vol.15 (8), p.1351-1360

2020

Volltextzugriff (PDF)

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1909-1924

2021

Volltextzugriff (PDF)

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339

2020

Volltextzugriff (PDF)

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Clinical cancer research, 2021-02, Vol.27 (3), p.877-888

2021

Volltextzugriff (PDF)

USP7 small-molecule inhibitors interfere with ubiquitin binding

Nature (London), 2017-10, Vol.550 (7677), p.534-538

2017

Volltextzugriff (PDF)

Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX

Molecular therapy, 2000-03, Vol.1 (3), p.225-235

2000

Volltextzugriff (PDF)

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations

Expert review of respiratory medicine, 2020-02, Vol.14 (2), p.125-136

2020

Volltextzugriff (PDF)

SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer

The Journal of cell biology, 2018-02, Vol.217 (2), p.763-777

2018

Volltextzugriff (PDF)

Abstract 406: Enhancer templated RNAs as predictors of therapeutic response to epigenetic therapy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.406-406

2016

Volltextzugriff (PDF)

Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT076-CT076

2018

Volltextzugriff (PDF)

Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter

Blood, 2000-04, Vol.95 (8), p.2536-2542

2000

Volltextzugriff (PDF)

Purification of the Ndc80 kinetochore subcomplex from Xenopus eggs

Methods in molecular biology (Clifton, N.J.), 2005, Vol.296, p.383

2005

Volltextzugriff (PDF)

Machine learning-based identification of predictive features of the tumor micro-environment and vasculature in NSCLC patients using the IMpower150 study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3130-3130

2020

Volltextzugriff (PDF)

Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT220-CT220

2020

Volltextzugriff (PDF)

26 – 50 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(58)

Publikationsform

Sprache

Englisch
(62)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(37)
Humans
(25)
Animals
(22)
Oncology
(15)
Tumors
(13)
Cell Biology
(11)
Immunotherapy
(11)
Lung Neoplasms - Drug Therapy
(11)
Lung Cancer
(10)
Mice
(10)
Cell Line, Tumor
(9)
Chemotherapy
(9)
Female
(9)
Mutation
(9)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Atezolizumab
(7)
Cancer Therapies
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Vertebrate Ndc80 Complex Contains Spc24 and Spc25 Homologs, which Are Required to Establish and Maintain Kinetochore-Microtubule Attachment

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Influence of cyclin type and dose on mitotic entry and progression in the early Drosophila embryo

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

Measuring the stoichiometry and physical interactions between components elucidates the architecture of the vertebrate kinetochore

831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials

28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology

Microenvironmental regulation of tumour immunity and response to immunotherapy

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

USP7 small-molecule inhibitors interfere with ubiquitin binding

Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations

SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer

Abstract 406: Enhancer templated RNAs as predictors of therapeutic response to epigenetic therapy

Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups

Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter

Purification of the Ndc80 kinetochore subcomplex from Xenopus eggs

Machine learning-based identification of predictive features of the tumor micro-environment and vasculature in NSCLC patients using the IMpower150 study

Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Suchergebnisse filtern